Evidence map›Paper›PMID 38962287›Full record

ArticleEuropean journal of medicinal chemistry reports2024

Improved

Masahide Yano, Jessica M Lawson-Rulli, Reilly M Coates, Jennifer Heldring, Marvin J Miller, Rui Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Masahide YanoMicrobiology, Hsiri Therapeutics, Inc, Media, PA, 19063, USA.
Jessica M Lawson-RulliMicrobiology, Hsiri Therapeutics, Inc, Media, PA, 19063, USA.
Reilly M CoatesMicrobiology, Hsiri Therapeutics, Inc, Media, PA, 19063, USA.
Jennifer HeldringMicrobiology, Hsiri Therapeutics, Inc, Media, PA, 19063, USA.
Marvin J MillerDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA.
Rui LiuDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA.

Funding

Design, Syntheses and Studies of Novel Antituberculosis AgentsR37AI054193 · NIAID · UNIVERSITY OF NOTRE DAME · PI MILLER, MARVIN J · 2016 to 2025
$5.2M
Design/Syntheses/Studies/Novel Antituberculosis AgentsR01AI054193 · NIAID · UNIVERSITY OF NOTRE DAME · PI MILLER, MARVIN J · 2004 to 2014
$3.2M
NIAID NIH HHS R01 AI054193NIAID NIH HHS R37 AI054193
6 · The paper itself

Abstract

Globally, millions of infections that are resistant to antimicrobial agents are reported annually, leading to more than 700,000 fatalities. Among all, challenges arise particularly from nontuberculosis mycobacterial (NTM) and Gram-negative bacteria, as they exhibit limited treatment options in light of increasing reports of multi-drug resistant strains. Clofazimine (CFZ) is an antimycobacterial medication used to treat leprosy, and it is also known for its side effect of inducing skin pigmentation. The use of CFZ and its analogues against a broad range of Gram-negative bacteria has not been extensively investigated. In this study, we designed, synthesized and studied 11 CFZ analogues and identified examples with comparable or improved

Identifiers

PMID38962287
PMCPMC11218832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.